

Greg Fenton Discusses Zentek's 2024 Progress and Exclusive Aptamer Technology Rights

written by InvestorNews | February 21, 2024

In a detailed interview with Tracy Weslosky, Greg Fenton, CEO and Director of [Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN), shared insights into the company's strategic progress and emerging opportunities, particularly emphasizing its work with aptamer technology. With an exclusive global license for innovative Aptamer-based platform technology developed by McMaster University, Zentek is pioneering advances in both diagnostic and therapeutic applications, underscoring its dedication to healthcare innovation. The company has made notable breakthroughs in COVID-19 therapeutics with its [C19HBA aptamer](#), showing significant promise in preclinical trials by outperforming leading monoclonal antibodies. This success has paved the way for Phase 1 clinical trials for COVID-19 and exploration into other areas such as oncology, immunology, and neurology.

Fenton highlighted the positive reception from major pharmaceutical companies, reflecting a broad industry interest in Zentek's aptamer technology. Additionally, Zentek's ZenGUARD™ technology platform, known for its 99-percent anti-microbial activity, has been instrumental in enhancing the bacterial and viral filtration efficiency of surgical masks and HVAC systems. A [recent study](#) on ZenGUARD™ Enhanced Air Filters revealed its potential to offer significant energy, emission, and cost savings for commercial buildings, showcasing a scalable solution for improving indoor air quality and addressing climate change.

Throughout the conversation, Fenton articulated Zentek's

ambitious plans for partnerships and expansion, leveraging the favorable market conditions to boost the company's visibility and impact. His vision for Zentek includes strategic partnerships, leveraging its proprietary technology, and a commitment to revolutionizing the approach to managing infectious diseases and enhancing environmental sustainability.

To access the complete interview, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek, through its wholly-owned subsidiary Triera Biosciences Ltd., has a global exclusive license to the Aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.

The Company is not making any express or implied claims that its aptamer technology has the ability to eliminate, cure or contain COVID-19 (or the SARS-CoV-2 coronavirus) at this time.

To learn more about Zentek Ltd., [click here](#)

Disclaimer: Zentek Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. ("InvestorNews"), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this "presentation") does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company's profile on [SedarPlus.ca](https://www.SedarPlus.ca) and to carry out independent investigations in order to determine their interest in investing in the Company.

Greg Fenton on the impact of Zentek's HVAC Phase 2 Testing results on Air Filtration

written by InvestorNews | February 21, 2024

The ZenGUARD™ coating can be applied to existing HVAC filters without having to do any modification to the HVAC systems and can increase filtration efficiency of the Phi6 virus, a surrogate for COVID-19 during a single air exchange of a MERV 8 filter by almost 5 times. In this InvestorIntel interview, Zentek's Greg Fenton discusses the results of the final report for Phase 2 testing of ZenGUARD™ for use in Heating, Ventilation

and Air Conditioning (“HVAC”) filtration from the National Research Council of Canada (“NRC”).

Zentek in the Global Spotlight for ZenGUARD™ Technology Patent

written by InvestorNews | February 21, 2024

[Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN), an IP development and commercialization company, has recently achieved a major milestone with their revolutionary product, ZenGUARD™ Technology. As of [December 2022](#), all 54 claims in the company’s Canadian patent application were granted by the Canadian Intellectual Property Office (CIP0). This momentous achievement is an essential step in obtaining global patent protection for ZenGUARD™ Technology.

The result of two years of research and testing by 21 global partners, the ZenGUARD™ Technology is a cutting-edge nanotechnology based on their graphene-oxide silver compound designed to create an invisible barrier on the surface of the mask.

In order to evaluate the performance of ZenGUARD™ masks compared to standard surgical masks, American Society for Testing and Materials (ASTM) Level 3, 3-ply uncoated masks were used as a comparison group. The results showed that the ZenGUARD™ masks had 98.9% more bacterial removal efficiency and 97.8% more virus removal efficiency than standard surgical masks. Furthermore,

these results were achieved with minimal added weight or bulkiness to the face masks, meaning they remain comfortable while providing superior protection against bacteria and viruses.

Zentek's accomplishment of getting a patent for their ZenGUARD™ technology for personal protective equipment and heating, ventilation, and air conditioning applications marks a significant milestone for the company and could set them up for success globally. This accomplishment took just two years from concept to fully protected asset.

CEO Greg Fenton's leading Zentek highlights their devotion to technology. The dedication to developing the concept and transforming it into a potential revenue-generating asset shows not only the commitment of Mr. Fenton but also Zentek as a whole. They have made great strides in an efficient amount of time and with promising results. This result highlights their capacity to take ideas from the lab bench to the market with patent protection.

With this success comes validation of their business model and a platform from which to extend their rights globally; plans are underway to eventually launch ZenGUARD™ Technology worldwide. Zentek also recently announced they are working with patent attorneys to extend patent protection of commercial rights on a global scale. This collaboration is an exciting example of how two organizations can use their collective knowledge to ensure businesses can maximize their intellectual property rights across international borders.

Patent protection extends beyond copyright and trademark law, making it essential for modern companies to understand worldwide patent regulations in order to capitalize on their innovations. By relying on the expertise of IP counsel, Zentek will likely

take full advantage of their rights across the globe.

This achievement not only validates Zentek's business model but also demonstrates that its product is both effective and marketable on a global scale. The ability to extend patent protection internationally opens many doors of opportunity for the company; they can now capitalize on their existing investments while also exploring new markets that were previously unavailable due to a lack of legal protection or recognition of intellectual property rights outside Canada's borders. With access to these new markets, there are a number of possibilities ahead for the company—especially when it comes to expanding its customer base and revenue stream potential.

In summary, Zentek Ltd.'s recent achievement of getting a patent for ZenGUARD™ marks an important milestone in the company's history—one that will potentially lead them down a path toward success both domestically and abroad. With access to new markets made available through patent protection globally, this opens up many opportunities for growth within the industry. As we look forward to 2023, we can continue to look for new developments ahead from Zentek Ltd., especially with regard to its revolutionary product ZenGUARD™ Technology.

**Zentek's revolutionary
graphene based icephobic**

coating targets billion dollar ice-resistant market

written by Tracy Weslosky | February 21, 2024

Ice build-up on wind turbines, airplanes, and cars in cold regions is a real problem. For example, Texas residents may remember the February 2021 ice storms and extreme cold weather that hit south-central USA. The storm resulted in over [4.5 million](#) homes and businesses being without power for several days. Frozen gas lines and ice buildup on wind turbines were key factors in the power failure as wind generation dropped by [almost 50%](#) over the entire state of Texas.

The airline industry spends significant time and money 'deicing' (removing ice and snow build-up) on their planes before take-off. Consumers in cold countries often have to do the same with their car windscreen. The drone market is another industry where deicing is important.

Now there is a better solution to de-icing. Today's company has developed an 'icephobic coating' technology that is effective at preventing ice build-up. '[Icephobic](#)' effectively translates to 'repelling ice'. It is also sometimes referred to as 'ice-resistant coating'.

The global market for ice-resistant (icephobic) coatings

It has been reported that the global market for ice-resistant coatings is forecast to reach [more than \\$1 billion in 2023](#), growing at a CAGR of 23.3%.

An excerpt from a 2021 report on the ice-resistant coatings and surfaces market



Source: [ResearchAndMarkets](#)

[Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN) [announced](#) in September strong test results supporting their [patent-pending](#), graphene-based, icephobic coating technology. The testing concluded that Zentek's icephobic technology is durable in adverse conditions for both wind turbine and drone industries, which are the initial focus markets for Zentek's icephobic coating.

Zentek [state](#) that their icephobic "coatings have demonstrated an adhesion strength repeatedly around 20 kPa (results under 100 kPa are considered to demonstrate low adhesion), a significant improvement over the current commercial products. Testing at the [National Research Council](#) (NRC) and [Anti-icing Materials International Laboratory](#) (AMIL) in Quebec is ongoing."

Some of the September [announcement](#) highlights included:

- "Flight tests in real-world icing conditions demonstrated good performance of Zentek's coating, with results indicating retardation of ice accretion (icephobicity) and low adhesion to accreted ice...
- Sand erosion testing demonstrated medium to good performance at a high speed of 540 km/h.
- Rain erosion testing at AMIL demonstrated good performance at 160 km/h and 320 km/h based on our interpretation, speeds at which the leading edge of wind turbines blade tips are exposed.
- NRC drone testing demonstrated consistent results of maintaining control of rotor thrust in icing conditions....
- Zentek has filed a full patent application with the Patent Cooperation Treaty, the international patent office, on August 2nd, 2022, for Nanomaterial-Enhanced Elastomer for Passive Ice Accretion Prevention."

[Source](#)

Icephobic coatings have many applications and significant demand

An exciting part of the above news is the potential for Zentek's technology to be used in a huge variety of uses globally, particularly the energy and aviation/aerospace industries.

Zentek [states](#):

"Commercial applications of our patent-pending coating could be used in drone technologies allowing for efficient all-weather operation. Other additional applications include powerlines, large wind turbines, ship structures (railings, etc.), and oil rigs, especially in Arctic operations, along with tall buildings where ice buildup could pose a public hazard."

Icephobic coatings could revolutionize aviation and wind power generation industries



Source: [Zentek website/icephobics](https://www.zentek.com/icephobics)

In addition to their icephobic coatings Zentek is also advancing multiple other initiatives including the commercialization of their "[Canada patent allowed](#)" [ZenGUARD™](#) (a 'graphene-silver coating' shown to have [99% antimicrobial activity](#) used on masks or PPE, also used in HVAC systems to improve air quality), aptamer enabled [Pathogen Detection Technology](#), [anti-inflammatory therapies](#), [fuel additives](#) (to reduce carbon emissions), [conductive filaments](#) for 3D printing, [fire retardant coatings](#), and [graphene wrapped silicon anodes](#) for batteries.

Zentek Ltd. trades on a market cap of [C\\$235 million](#) on the TSXV or [US\\$175 million](#) on the Nasdaq.

Greg Fenton of Zentek on its new mask manufacturing agreement and US interest in its HVAC filters

written by InvestorNews | February 21, 2024

In this InvestorIntel interview, host Tracy Weslosky talks to [Zentek Ltd.](#)'s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about its new mask manufacturing and packaging agreement and interest generated from a successful promotional tour in the USA.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel ([click here to access InvestorChannel.com](#)), Greg discusses how Zentek has entered into an agreement with long-established Viva Healthcare Packaging (Canada) Ltd. to manufacture and sell surgical masks enhanced with Zentek's proprietary ZenGUARD antimicrobial coating. At the height of the pandemic Viva was producing over 20 million masks per month. "They're big and well established with an existing distribution network," Greg tells Tracy, "so it was absolutely a perfect partnership for us."

Greg also talks about his recent visit to Washington, D.C., that included 14 meetings with members of the U.S. Congress, to discuss indoor air quality and Zentek's ZenGUARD-coated HVAC filters. "We developed a lot of momentum there," he says. He also talks about ongoing testing of their HVAC filters in real world environments, like classrooms. "The simplicity and

elegance of our solution is it's a passive solution that can be added to any existing system."

Finally, Greg also talks about Zentek's finances. "We did a significant capital raise at the beginning of this year and our treasury's in an excellent position," he tells Tracy, "but we're being very judicious in our spending."

To access the full InvestorIntel interview, [click here](#)

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#).

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek's proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.

To know more about Zentek Ltd., [click here](#)

Disclaimer: *Zentek Ltd. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements"

within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Zentek CEO Greg Fenton talks

about bringing new antimicrobial HVAC filters to market

written by InvestorNews | February 21, 2024

In this InvestorIntel interview with host Tracy Weslosky, [Zentek Ltd.](#)'s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton talks about new opportunities and commercial applications for their unique Zenguard antimicrobial coating.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel ([click here](#)), Greg tells Tracy "we're focused quite acutely on the HVAC sector right now. We're testing our unique antimicrobial coating on HVAC filters. Our Zenguard coating has been demonstrated to be effective against most airborne pathogens." The interest in applying Zenguard to HVAC filters came out of a Canadian government call for new technologies to fight Covid-19, and Zentek won phase one of the challenges and is now onto phase two testing in real-world environments.

"If we're successful," Greg tells Tracy, "then the Government of Canada becomes an immediate client of ours and they will procure from us for a period of three years minimum." He continues that the person in charge of the government testing facility "has told us that he has not seen anything even close to what we've been able to achieve so far, so we're very excited about this and think we could have this product in the market later this year."

To access the full InvestorIntel interview, [click here](#)

Don't miss other InvestorIntel interviews. Subscribe to the

InvestorIntel YouTube channel by [clicking here](#).

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have over 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

To know more about Zentek Ltd., [click here](#)

Disclaimer: *Zentek Ltd. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems

immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Greg Fenton of Zentek discusses recent news including a NASDAQ listing and a distribution agreement

written by InvestorNews | February 21, 2024

In this InvestorIntel interview with host Tracy Weslosky, [Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton talks about Zentek's substantial recent newsflow, including listing on NASDAQ and announcing [sales and distribution](#) of

ZenGUARD™ coated-masks through Mark's in Canada.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel ([click here](#)), Greg Fenton talks about other recent announcements including the start of Phase 2 testing of ZenGUARD™ antimicrobial coating on HVAC filters under a contract with Innovation Solutions Canada (ISC). He goes on to say that on the success of Phase 2, Zentek can add the Government of Canada as a client as well as opening up new opportunities for sales and distribution. Greg also provides an update on Zentek's portfolio of patents including the filing of a provisional patent for their [fire-retardant additive](#).

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#).

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

To know more about Zentek Ltd., [click here](#)

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company"

being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

With technology for the real world, Zentek's graphene nanotech masks are now on store shelves

written by InvestorNews | February 21, 2024

At the start of the year, I was asked to pick a name that I thought could be the "[stock to watch in 2022](#)". Naturally the tendency is to step a little further out the risk curve because where's the fun in picking something like Enbridge, Inc. (TSX: ENB | NYSE: ENB) and being up 15% year-to-date plus dividend when you could be up 130% over that same time period with a stock like Ensign Energy Services, Inc. (TSX: ESI). In reality, I would have been a hero if I had picked either of those in light of what the majority of the market has done since the start of 2022. However, I went down the technology route (or should I say rout) and the name I picked has been swept lower in a market beating up anything resembling tech. On top of that, the company I selected was also the focus of a short report, although that appears to have been [addressed in March](#) and seems to be a non-issue. But technology stocks are still seeing some pretty unpleasant days here and there, and the pain may not be over yet.

Nevertheless, until the year is over, I still have time to be vindicated with my 2022 pick – [Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN), which is certainly doing better than Shopify, Inc. (TSX: SHOP | NYSE: SHOP) but sadly that's not setting the bar too high. Reader's will recall that Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment.

Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases.

The focus on ZenGUARD™ is paying off with an announcement last week of the [sales and distribution of ZenGUARD™ Masks](#) through Mark's, a member of the Canadian Tire Family of Companies. Mark's, which operates over 380 stores across Canada, has placed an initial order for ZenGUARD™ coated masks to be sold at select stores and online. Mark's VP Iain Summers is quoted as saying "We are relentlessly focused on innovative new technologies and products that help keep Canadians safe and comfortable. Zentek, and their ZenGUARD™ masks are a great made-in-Canada innovation using a technology that, when applied to essential masks, provides ultimate protection, while maintaining comfort and breathability. It's the right fit for our customers." This news helped Zentek stock rally 14% on the day.

It was the progress the Company was making with ZenGUARD™ and their other unique IP opportunities that led to Zentek being my stock to watch. Other technologies under development include an icephobic coating that can potentially be used to improve aircraft and drone safety and sustainability. The Company anticipates applications for aircraft, wind turbines, ocean vessels, and building structures to increase safety and efficiency outcomes in ice-forming weather conditions. The Company recently reported [excellent results in three rounds of testing](#) of its icephobic coating, including laboratory tests, real-world flights and applications related to drone operations in adverse weather. Next steps include testing its coating for sand and rain erosion, and other tests are being planned that will evaluate the coating as part of a hybrid ice protection system, where the icephobic properties are combined with a heated de-icing system with the aim to improve efficiency of

current ice protection methods used in general and commercial aviation.

In April, Zentek provided an update on a previously awarded R&D test contract through the Innovation Solutions Canada (ISC) Testing Stream [to test ZENGuard™ coated HVAC filters](#) with interest from 3 different units within the National Research Council of Canada. After completion of Phase 1 testing where its ZenGUARD™ coating was successful in reducing airborne organisms from passing through coated filter material while not inhibiting air flow, it will now [proceed to Phase 2 testing](#) within its ISC Testing Stream contract. Phase 2 testing in a real-world classroom environment is aimed to generate additional safety and efficacy data. The importance of indoor air quality and improving health is a top priority for numerous organizations globally, including the Canadian and [U.S. governments](#), and could be an important commercialization milestone for Zentek in this critical area.

Sure all these initiatives were already on the go at the start of the year, but in my opinion, the Company is making great strides in pushing these projects to the revenue generation stage. In fact, ZenGAURD™ actually started generating revenue in the final quarter of 2021. Additionally, Zentek raised C\$33 million in January and have a quarterly cash burn rate of roughly C\$2-C\$2.5 million per quarter (and no debt), so they should be fine for available capital. With a market cap of roughly C\$247 million there are plenty of creative and unique opportunities being developed to propel this Company into the future and vindicate my selection.

How NASDAQ listed Zentek is a 'wow' company with enormous potential to tap into several multi-billion dollar industries.

written by InvestorNews | February 21, 2024

Every once in a while investors will come across a 'wow' company. This is a company that just wows you with their performance and their stock price.

For me the 'wow' company of the last year is [Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN). Just take a look at the stock chart below, showing the stock rising a staggering 9.7x over the past approximately year and a half. The good news for investors is that the recent pullback allows for a better entry price than when the stock peaked at C\$6.50.

Zentek Ltd (TSXV: ZEN) 5 year stock price chart



Source: [Yahoo Finance](#)

Today I give a brief summary of Zentek for new investors and an update on their progress in 2022.

Zentek's business summary

Zentek [describe](#) themselves as "an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment."

I prefer to think of them as a nanotechnology and graphene company (they were formerly known as ZEN Graphene Solutions) that has expanded into multiple areas of commercialization; particularly into the healthcare sector with a product for prevention, detection and treatment of numerous pathogens.

Areas/products of commercialization for Zentek include:

- [ZenGUARD™](#) – A patent-pending ‘graphene-silver coating’ shown to have [99% antimicrobial activity](#), including against COVID-19. The coating can be used for PPE applications (including nitrile gloves, gowns, footwear coverings and surgical caps) and also in air purifiers. [According to](#) Zentek: “ZenGUARD™-coated masks removed 98.9% more bacteria and 97.8% more virus compared to a typical ASTM Level 3, 3-ply uncoated, resulting in over 99.99% BFE and VFE ratings.” ZenGUARD™ has [Health Canada approval](#) (Medical Device Establishment License, “MDEL”) and [production facilities are being readied for first orders.](#) Zentek is commercializing ZENGuard™ with mask manufacturer Trebor Rx, but can also work with other manufacturers.
- [Pathogen Detection Technology](#) (aptamer-enabled) – A low cost, rapid, saliva testing, scalable technology to detect numerous pathogens, initially to be used for COVID-19 testing.
- [Antimicrobial therapies](#) – In-vitro testing shows [99.9% effectiveness](#) against bacteria, fungi and viruses.
- **Air conditioner filter coating** – Zentek has experimented with past partners to use graphene oxide coated filters to help remove moisture from the air and make air conditioners up to [75% more energy efficient.](#)
- [Icephobic graphene coatings](#) – Potential to significantly increase safety for vehicles such as drones, aircraft,

ocean vessels, wind turbines, and other applications where, in cold weather climates, there is the potential for ice to accrete on surfaces. An 'icephobic' surface repels ice build up.

- **Others** – Graphene tires, graphene in concrete, [fuel additives](#) (potential to reduce GHG emissions from diesel and bio-diesel fuels by as much as 10%), and graphene for batteries.

Zentek's latest news and progress in 2022

Zentek announced on [February 18, 2022](#) the development of graphene-wrapped silicon anodes. Zentek CEO Greg Fenton [stated](#): "Not only were the researchers able to demonstrate good performance with laboratory-scale half-cells, the performance was also validated with commercial lithium iron phosphate cathodes suggesting they could be a drop-in solution for enhancing already available battery technologies. We look forward to continuing our support of their research and development to potentially bring this technology to market. The company has begun discussions with a potential industry partner."

As [reported](#) on February 28, 2022, Zentek's Guelph production facility is now fully licensed and permitted for ZenGUARD™ production and substantially all equipment has been received to ramp-up industrial scale capacity. First orders have been received and the ZenGUARD™ international patent is due shortly. As [reported](#) on January 13, Zentek has entered into a binding letter of intent with GMAF Circular Medico ApS to produce and sell ZENGuard™-enhanced GMAF trademarked recyclable surgical masks.

With regards to the Pathogen Detection Technology, Zentek [continues to work to bring the product to market](#) as soon as practicable, which will require having a working prototype

prepared, having conducted baseline studies, and having made applications to regulatory bodies.

With regards to Zentek's icephobic coatings, they are currently [undergoing full flight trials](#) on a specially equipped research aircraft under real world ice-forming weather conditions.

Zentek's new manufacturing facility in Guelph, Ontario, Canada is set for commissioning shortly



Source: [Zentek website](#)

Closing remarks

Zentek really is a 'wow' company with enormous potential to tap into several multi-billion dollar industries. Focusing on pathogens (viruses, bacteria, fungi) prevention, detection, and treatment is simply staggering. Then there are multiple other applications for Zentek's products, the most recent being graphene-wrapped silicon anodes that can potentially be used to create better EV batteries and the icephobic coatings opportunity.

In terms of commercialization, Zentek is already advancing with ZenGUARD™ in terms of a production facility and orders, with the ZenGUARD™ patent due very soon and production from Zentek's new Guelph facility set to begin very soon.

Finally, Zentek is now getting the exposure it deserves with [a NASDAQ listing](#) that began on March 22, 2022, under the ticker "ZTEK". Not surprisingly the stock [rose 25.93%](#) on March 23.

Zentek has [C\\$32 million](#) in cash, no debt, and looks like being a 'wow' company again in 2022. Stay tuned.

Disclosure: The author is long Zentek (TSXV: ZEN).

Greg Fenton on Zentek's approval for Nasdaq listing and the expanding use of its highly effective anti-microbial ZenGUARD™ coating

written by InvestorNews | February 21, 2024

In a recent InvestorIntel interview, Tracy Weslosky spoke with Greg Fenton, CEO and Director of [Zentek Ltd.](#) (TSXV: ZEN) about Zentek's recent [news release](#) on receiving approval to list on the Nasdaq and about [engaging Vimta Labs](#) to begin studies of ZenGUARD™ active ingredient as a potential treatment of infectious skin disease.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Greg Fenton provided an update on Zentek's "unique and innovative" ZenGUARD™ antimicrobial coating which is "proven to be more than 99% effective in reducing the physical spread of the SARS-CoV-2" and other pathogens. He went on to say that Zentek will be publishing the patent application for the ZenGUARD™ antimicrobial coating on March 21, 2022.

To watch the full interview, [click here](#).

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% effectiveness in antimicrobial activity reduction, including against the COVID-19 pathogens, and the potential to use similar compounds as products against other infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed rapid aptamer-based pathogen detection technology.

To learn more about Zentek Ltd., [click here](#).

Disclaimer: *Zentek Ltd. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as

objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.